The Role of Matrix Metalloproteinase 2 and 9 Enzymes in Developing Chronic Thromboembolic Pulmonary Hypertension

AHMET ZENGIN

Status: Completed

Conditions: Chronic Thromboembolic Pulmonary Hypertension

Treatments: Other: matrix metalloproteinase enzymes 2 and 9

Study type: Observational

Funder types: Other

Identifiers

NCT04773028

2020-071

Details and patient eligibility

About

Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery.Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling. The clot formed in chronic thromboembolic pulmonary hypertension does not melt and turns into a fibrous state, it occludes the pulmonary artery.In this study, investigators aimed to investigate the role of matrix metalloproteinase enzymes in pulmonary arterial wall remodeling in patients with chronic thromboembolic pulmonary hypertension

Full description

Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery. Only 4% of patients with acute pulmonary embolism develop chronic thromboembolic pulmonary hypertension and acute pulmonary embolism or deep vein thrombosis is reported in the anamnesis of 75% of those with chronic thromboembolic disease. Therefore, the etiology of the disease is not clear. Altought many studies are done, especially the role of inflamation is emhasised underlie the disease.

Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling. The clot formed in chronic thromboembolic pulmonary hypertension does not melt and turns into a fibrous state, it occludes the pulmonary artery.In this study, investigators aimed to investigate the role of matrix metalloproteinase enzymes in pulmonary arterial wall remodeling in patients with chronic thromboembolic pulmonary hypertension.

Matrix metalloprotinase enzymes are known to play a role in atherosclerosis. This research will investigate whether there is atherosclerosis together with inflamattion in the background of chronic thromboembolic hypertension.

Enrollment: 48 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Despite 3 months of anticoagulation therapy
• mean pulmonary arterial pressure > 20 mmHg
• pulmonary vasculary resistance > 3 wood
• pulmonary capillary wedge pressure < 15 mmHg
• perfusion defect in ventilation perfusion scintigraphy
• pulmonary angiography or computed tomography angiography showing pulmonary artery occlusive lesions

Exclusion criteria

• Patients undergoing pulmonary thromboendarterectomy concomitant coronary bypass, carotid endarterectomy, aortic valve, ascending aorta, mitral valve, tricuspid valve, pulmonary valve surgery
• Patients who have undergone surgical or percutaneous procedures due to atherosclerotic disease

Trial design

48 participants in 2 patient groups

PATİENT GROUP(GROUP 1)

Description:

This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.

Treatment:

Other: matrix metalloproteinase enzymes 2 and 9

CONTROL GROUP(GROUP 2)

Description:

This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.

Treatment:

Other: matrix metalloproteinase enzymes 2 and 9